Middle East & Africa Next Generation Antibody Therapeutics Market Research Report - Segmented By Therapeutics, Technology & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, Growth, Forecast | 2024 to 2029
Middle East & Africa Next Generation Antibody Therapeutics Market Size & Growth (2024 to 2029)
As Per the Report, the Middle East & Africa Next Generation Antibody Therapeutics Market size is valued at USD 30.77 billion in 2024 and is expected to grow at a CAGR of 2.6% to reach USD 34.98 billion by 2029 during the forecast period 2024 to 2029. It captures 8% of the global market share.
Next generation antibody therapeutics have high efficiency and are safer. Rapid advancements in monoclonal antibodies technology are the reason for this. These advances have improved bifunctional properties, decreased functional size along with immunogenicity. Several medical conditions like cancer; autoimmune diseases, etc. are treated using these technologies because of its enhanced properties.
A rising number of cases of chronic diseases, rapid advancements in technology, higher investment in R&D and increasing healthcare expenditure are the primary drivers of market growth. On the other hand, strict administrative guidelines and regulatory requirements and inordinate delays in approval for new drugs along with their high costs are the primary restraints of market growth.
Middle East & Africa Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories
-
By Therapeutics: Oncology and Autoimmune/Inflammatory Diseases
- By Technology: Antibody-Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-like Proteins, and Biosimilar Antibody Products.
- By Country: KSA, UAE, Israel, the rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA.
On the basis of region, MEA continues to be the least attractive market in the forecast period.
Key Market Companies dominating the Middle East & Africa Next Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]